BACKGROUND: The peak incidence of Ewing sarcoma (EWS) is in adolescence, with little known about patients who are ≥40 years at diagnosis. We describe the clinical characteristics and survival of this rare group. METHODS: This retrospective cohort study utilized the Surveillance Epidemiology and End Results database. 2780 patients were identified; including 383 patients diagnosed ≥40 years. Patient characteristics between age groups were compared using chi-squared tests. Survival from diagnosis to death was estimated via Kaplan-Meier methods, compared with log-rank tests, and modeled using multivariable Cox methods. A competing risks analysis was performed to evaluate death due to cancer. RESULTS: Patients ≥40 years of age were more likely to have extra-skeletal tumors (66.1% vs. 31.7%; p < 0.001), axial tumors (64.0% vs. 57.2%; p = 0.01), and metastatic disease at diagnosis (35.5% vs. 30.0%; p = 0.04) compared to younger patients. Five-year survival for those age ≥40 and age <40 were 40.6% and 54.3%, respectively (p < 0.0001). A Cox multivariable model controlling for differences between groups confirmed inferior survival for older patients (hazard ratio for death of 2.04; 95% CI 1.63-2.54; p < 0.0001); though treatment data were unavailable and not controlled for in the model. A competing risks analysis confirmed increased risk of cancer-related death in older patients. CONCLUSION: Patients ≥40 years at diagnosis with EWS are more likely to have extra-skeletal tumors, metastatic disease, and axial primary tumors suggesting a difference in tumor biology. Independent of differences in these characteristics, older patients also have a lower survival rate.
BACKGROUND: The peak incidence of Ewing sarcoma (EWS) is in adolescence, with little known about patients who are ≥40 years at diagnosis. We describe the clinical characteristics and survival of this rare group. METHODS: This retrospective cohort study utilized the Surveillance Epidemiology and End Results database. 2780 patients were identified; including 383 patients diagnosed ≥40 years. Patient characteristics between age groups were compared using chi-squared tests. Survival from diagnosis to death was estimated via Kaplan-Meier methods, compared with log-rank tests, and modeled using multivariable Cox methods. A competing risks analysis was performed to evaluate death due to cancer. RESULTS:Patients ≥40 years of age were more likely to have extra-skeletal tumors (66.1% vs. 31.7%; p < 0.001), axial tumors (64.0% vs. 57.2%; p = 0.01), and metastatic disease at diagnosis (35.5% vs. 30.0%; p = 0.04) compared to younger patients. Five-year survival for those age ≥40 and age <40 were 40.6% and 54.3%, respectively (p < 0.0001). A Cox multivariable model controlling for differences between groups confirmed inferior survival for older patients (hazard ratio for death of 2.04; 95% CI 1.63-2.54; p < 0.0001); though treatment data were unavailable and not controlled for in the model. A competing risks analysis confirmed increased risk of cancer-related death in older patients. CONCLUSION:Patients ≥40 years at diagnosis with EWS are more likely to have extra-skeletal tumors, metastatic disease, and axial primary tumors suggesting a difference in tumor biology. Independent of differences in these characteristics, older patients also have a lower survival rate.
Authors: Abha A Gupta; Alberto Pappo; Natasha Saunders; Sevan Hopyan; Peter Ferguson; Jay Wunder; Brian O'Sullivan; Charles Catton; Mark Greenberg; Martin Blackstein Journal: Cancer Date: 2010-07-01 Impact factor: 6.860
Authors: G Bacci; S Ferrari; A Comandone; A Zanone; P Ruggieri; A Longhi; F Bertoni; C Forni; M Versari; S Rimondini Journal: Acta Oncol Date: 2000 Impact factor: 4.089
Authors: Carlos Rodríguez-Galindo; Tiebin Liu; Matthew J Krasin; Jianrong Wu; Catherine A Billups; Najat C Daw; Sheri L Spunt; Bhaskar N Rao; Victor M Santana; Fariba Navid Journal: Cancer Date: 2007-07-15 Impact factor: 6.860
Authors: Muhammad U Jawad; Michael C Cheung; Elijah S Min; Michaela M Schneiderbauer; Leonidas G Koniaris; Sean P Scully Journal: Cancer Date: 2009-08-01 Impact factor: 6.860
Authors: Dagmar Adamkova Krakorova; Katerina Kubackova; Ladislav Dusek; Tomas Tomas; Pavel Janicek; Stepan Tucek; Jana Prausova; Igor Kiss; Iva Zambo Journal: Pathol Oncol Res Date: 2017-08-12 Impact factor: 3.201
Authors: David Boyce-Fappiano; B Ashleigh Guadagnolo; Ravin Ratan; Wei-Lien Wang; Michael J Wagner; Shreyaskumar Patel; John A Livingston; Patrick P Lin; Kevin Diao; Devarati Mitra; Ahsan Farooqi; Alexander J Lazar; Christina L Roland; Andrew J Bishop Journal: Oncologist Date: 2020-12-14
Authors: Jennifer L Pretz; Constance M Barysauskas; Suzanne George; Jason L Hornick; Chandrajit P Raut; Yen-Lin E Chen; Karen J Marcus; Edwin Choy; Francis Hornicek; John E Ready; Thomas F DeLaney; Elizabeth H Baldini Journal: Oncologist Date: 2017-05-26
Authors: Erin E Karski; Elizabeth McIlvaine; Mark R Segal; Mark Krailo; Holcombe E Grier; Linda Granowetter; Richard B Womer; Paul A Meyers; Judy Felgenhauer; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167
Authors: Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor Journal: Front Oncol Date: 2013-06-06 Impact factor: 6.244
Authors: Scott C Borinstein; Natalie Beeler; John J Block; Richard Gorlick; Patrick Grohar; Paul Jedlicka; Mark Krailo; Carol Morris; Sharon Phillips; Gene P Siegal; Elizabeth R Lawlor; Stephen L Lessnick Journal: Front Oncol Date: 2013-03-20 Impact factor: 6.244
Authors: Atreyi Dasgupta; Matteo Trucco; Nino Rainusso; Ronald J Bernardi; Ryan Shuck; Lyazat Kurenbekova; David M Loeb; Jason T Yustein Journal: Oncotarget Date: 2017-08-24